

# Summary of Product Characteristics

## 1 NAME OF THE MEDICINAL PRODUCT

Metoclopramide 5mg/ml Solution for Injection

## 2 QUALITATIVE AND QUANTITATIVE COMPOSITION

Each 2 ml contains metoclopramide hydrochloride equivalent to 10 mg of anhydrous metoclopramide hydrochloride.

Excipient(s) with known effect:

Sodium Metabisulphite (E223) 2.0mg

For a full list of excipients, see section 6.1.

## 3 PHARMACEUTICAL FORM

Solution for injection

Clear colourless sterile solution.

## 4 CLINICAL PARTICULARS

### 4.1 Therapeutic Indications

Metoclopramide is indicated in adults for:

- Prevention of post operative nausea and vomiting (PONV)
- Symptomatic treatment of nausea and vomiting, including acute migraine induced nausea and vomiting
- Prevention of radiotherapy induced nausea and vomiting (RINV).

#### **Paediatric population:**

Metoclopramide is indicated in children (aged 1-18 years) for:

- Prevention of delayed chemotherapy induced nausea and vomiting (CINV) as a second line option
- Treatment of established post operative nausea and vomiting (PONV) as a second line option

Metoclopramide should not be used in children younger than 1 year as there are insufficient data regarding efficacy and safety of the product in this population.

### 4.2 Posology and method of administration

#### **Posology:**

#### **Route of Administration:**

The solution can be administered intravenously or intramuscularly.

Intravenous doses should be administered as a slow bolus (at least over 3 minutes).

#### **Adult population**

For prevention of PONV a single dose of 10mg is recommended.

For the symptomatic treatment of nausea and vomiting, including acute migraine induced nausea and vomiting and for the prevention of radiotherapy induced nausea and vomiting (RINV): the recommended single dose is 10 mg, repeated up to three times daily

The maximum recommended daily dose is 30 mg or 0.5mg/kg body weight.

The injectable treatment duration should be as short as possible and transfer to oral or rectal treatment should be made as soon as possible.

#### **All indications (paediatric patients aged 1-18 years)**

The recommended dose is 0.1 to 0.15 mg/kg body weight, repeated up to three times daily by intravenous route. The maximum dose in 24 hours is 0.5 mg/kg body weight.

Dosing table

Age	Body Weight	Dose	Frequency
1-3 years	10-14 kg	1 mg	Up to 3 times daily
3-5 years	15-19 kg	2 mg	Up to 3 times daily
5-9 years	20-29 kg	2.5 mg	Up to 3 times daily
9-18 years	30-60 kg	5 mg	Up to 3 times daily
15-18 years	Over 60kg	10 mg	Up to 3 times daily

The maximum treatment duration is 48 hours for treatment of established post operative nausea and vomiting (PONV).

The maximum treatment duration is 5 days for prevention of delayed chemotherapy induced nausea and vomiting (CINV).

#### Method of administration:

A minimal interval of 6 hours between two administrations is to be respected, even in case of vomiting or rejection of the dose (see section 4.4).

#### Special population

##### Elderly

In elderly patients a dose reduction should be considered, based on renal and hepatic function and overall frailty.

##### Renal impairment:

In patients with end stage renal disease (Creatinine clearance  $\leq$  15 ml/min), the daily dose should be reduced by 75%.

In patients with moderate to severe renal impairment (Creatinine clearance 15-60 ml/min), the dose should be reduced by 50% (see section 5.2).

##### Hepatic impairment:

In patients with severe hepatic impairment, the dose should be reduced by 50% (see section 5.2).

##### Paediatric population

Metoclopramide is contraindicated in children aged less than 1 year (see section 4.3).

### 4.3 Contraindications

- Hypersensitivity to the active substance or to any of the excipients listed in section 6.1
- Gastrointestinal haemorrhage, mechanical obstruction or gastro-intestinal perforation for which the stimulation of gastrointestinal motility constitutes a risk
- Confirmed or suspected pheochromocytoma, due to the risk of severe hypertension episodes
- History of neuroleptic or metoclopramide-induced tardive dyskinesia
- Epilepsy (increased crises frequency and intensity)
- Parkinson's disease
- Combination with levodopa or dopaminergic agonists (see section 4.5)
- Known history of methaemoglobinaemia with metoclopramide or of NADH cytochrome-b5 deficiency.
- Use in children less than 1 year of age due to an increased risk of extrapyramidal disorders (see section 4.4)

### 4.4 Special warnings and precautions for use

#### Neurological disorder

Extrapyramidal disorders may occur, particularly in children and young adults, and/or when high doses are used. These reactions occur usually at the beginning of the treatment and can occur after a single administration. Metoclopramide should be discontinued immediately in the event of extrapyramidal symptoms. These effects are generally completely reversible after treatment discontinuation, but may require a symptomatic treatment (benzodiazepines in children and/or anticholinergic anti-Parkinsonian medicinal products in adults).

The time interval of at least 6 hours specified in the section 4.2 should be respected between each metoclopramide administration, even in case of vomiting and rejection of the dose, in order to avoid overdose.

Prolonged treatment with metoclopramide may cause tardive dyskinesia, potentially irreversible, especially in the elderly. Treatment should not exceed 3 months because of the risk of tardive dyskinesia (see section 4.8). Treatment must be discontinued if clinical signs of tardive dyskinesia appear.

Neuroleptic malignant syndrome has been reported with metoclopramide in combination with neuroleptics as well as with metoclopramide monotherapy (see section 4.8).

Metoclopramide should be discontinued immediately in the event of symptoms of neuroleptic malignant syndrome and appropriate treatment should be initiated.

Metoclopramide should not be used during the first three to four days following operations such as pyloroplasty or gut anastomosis as vigorous muscular contractions may not help healing.

Special care should be exercised in patients with underlying neurological conditions and in patients being treated with other centrally-acting drugs (see section 4.3)

Symptoms of Parkinson's disease may also be exacerbated by metoclopramide.

### **Methaemoglobinemia**

Methemoglobinemia which could be related to NADH cytochrome b5 reductase deficiency has been reported. In such cases, metoclopramide should be immediately and permanently discontinued and appropriate measures initiated (such as treatment with methylene blue).

### **Cardiac Disorders**

There have been reports of serious cardiovascular undesirable effects including cases of circulatory collapse, severe bradycardia, cardiac arrest and QT prolongation following administration of metoclopramide by injection, particularly via the intravenous route (see section 4.8).

Special care should be taken when administering metoclopramide, particularly via the intravenous route to the elderly population, to patients with cardiac conduction disturbances (including QT prolongation), patients with uncorrected electrolyte imbalance, bradycardia and those taking other drugs known to prolong QT interval. Intravenous doses should be administered as a slow bolus (at least over 3 minutes) in order to reduce the risk of adverse effects (e.g. hypotension, akathisia).

Special care should be taken when administering to patients with "sick sinus syndrome" or other cardiac conduction disturbances.

### **Renal and Hepatic Impairment**

In patients with renal impairment or with severe hepatic impairment, a dose reduction is recommended (see section 4.2). If vomiting persists the patient should be reassessed to exclude the possibility of an underlying disorder e.g. cerebral irritation.

Metoclopramide may cause elevation of serum prolactin levels.

Care should be exercised when using Metoclopramide in patients with a history of atopy (including asthma) or porphyria.

## **4.5 Interaction with other medicinal products and other forms of interactions**

### **Contraindicated combination**

Levodopa or dopaminergic agonists and metoclopramide have a mutual antagonism (see section 4.3).

### **Combination to be avoided**

Alcohol potentiates the sedative effect of metoclopramide.

### **Combination to be taken into account**

Due to the prokinetic effect of metoclopramide, the absorption of certain drugs may be modified.

### **Anticholinergics and morphine derivatives**

Anticholinergics and morphine derivatives may have both a mutual antagonism with metoclopramide on the digestive tract motility.

The action of ' Metoclopramide ' on the gastrointestinal tract is antagonised by anticholinergics and opioid analgesics. The absorption of any concurrently administered oral medication may be modified by the effect of Metoclopramide on gastric motility. Drugs known to be affected in this way include aspirin and paracetamol.

Central nervous system depressants (morphine derivatives, anxiolytics, sedative H1 antihistamines, sedative antidepressants, barbiturates, clonidine and related)

Sedative effects of Central Nervous System depressants and metoclopramide are potentiated.

### **Neuroleptics**

Metoclopramide may have an additive effect with other neuroleptics on the occurrence of extrapyramidal disorders.

**Serotonergic drugs**

The use of metoclopramide with serotonergic drugs such as SSRIs may increase the risk of serotonin syndrome.

**Digoxin**

Metoclopramide may decrease digoxin bioavailability. Careful monitoring of digoxin plasma concentration is required.

**Cyclosporine**

Metoclopramide increases cyclosporine bioavailability (C<sub>max</sub> by 46% and exposure by 22%). Careful monitoring of cyclosporine plasma concentration is required. The clinical consequence is uncertain.

**Mivacurium and suxamethonium**

Metoclopramide injection may prolong the duration of neuromuscular block (through inhibition of plasma cholinesterase).

**Strong CYP2D6 inhibitors**

Metoclopramide exposure levels are increased when co-administered with strong CYP2D6 inhibitors such as fluoxetine and paroxetine. Although the clinical significance is uncertain, patients should be monitored for adverse reactions.

**4.6 Fertility, pregnancy and lactation****Pregnancy**

A large amount of data on pregnant women (more than 1000 exposed outcomes) indicates no malformative toxicity nor foetotoxicity. Metoclopramide can be used during pregnancy if clinically needed. Due to pharmacological properties (as other neuroleptics), in case of metoclopramide administration at the end of pregnancy, extrapyramidal syndrome in newborn cannot be excluded. Metoclopramide should be avoided at the end of pregnancy. If metoclopramide is used, neonatal monitoring should be undertaken.

**Breastfeeding**

Metoclopramide is excreted in breast milk at low level. Adverse reactions in the breast-fed baby cannot be excluded. Therefore, metoclopramide is not recommended during breastfeeding. Discontinuation of metoclopramide in breastfeeding women should be considered.

**4.7 Effects on ability to drive and use machines**

Metoclopramide has moderate influence on the ability to drive and use machines.

Metoclopramide may cause drowsiness, dizziness, dyskinesia, and dystonias which could affect the vision and also interfere with the ability to drive or operate machinery.

**4.8 Undesirable effects**

Adverse reactions listed by System Organ Class. Frequencies are defined using the following convention: very common ( $\geq 1/10$ ), common ( $\geq 1/100$ ,  $< 1/10$ ), uncommon ( $\geq 1/1000$ ,  $< 1/100$ ), rare ( $\geq 1/10000$ ,  $< 1/1000$ ), very rare ( $< 1/10000$ ), not known (cannot be estimated from the available data).

System Organ Class	Frequency	Adverse reactions
<b>Blood and lymphatic system disorders</b>		
	Not known	Methaemoglobinaemia, which could be related to NADH cytochrome b5 reductase deficiency, particularly in neonates (see section 4.4);  Sulphaemoglobinaemia, mainly with concomitant administration of high doses of sulphur-releasing medicinal products
<b>Cardiac disorders</b>		
	Uncommon	Bradycardia, particularly with intravenous formulation
	Not known	Cardiac arrest, occurring shortly after injectable use, and which can be subsequent to bradycardia (see section 4.4);

		Atrioventricular block, Sinus arrest particularly with intravenous formulation; Electrocardiogram QT prolonged; Torsade de Pointes;
<b>Respiratory, thoracic and mediastinal disorders</b>		
	Not known	Dyspnoea
<b>Endocrine disorders*</b>		
	Uncommon	Amenorrhoea, Hyperprolactinaemia,
	Rare	Galactorrhoea
	Not known	Gynaecomastia
<b>Gastrointestinal disorders</b>		
	Common	Diarrhoea
<b>General disorders and administration site conditions</b>		
	Common	Asthenia
	Rare	anxiety
	Not known	Oedema
<b>Eye disorders</b>		
	Not known	Visual disturbances
<b>Immune system disorders</b>		
	Uncommon	Hypersensitivity
	Not known	Anaphylactic reaction (including anaphylactic shock particularly with intravenous formulation, Skin reactions such as rashes, urticaria, pruritus and angioedema
<b>Nervous system disorders</b>		
	Very common	Somnolence
	Common	Extrapyramidal disorders (particularly in children and young adults and/or when the recommended dose is exceeded, even following administration of a single dose of the drug) (see section 4.4), Parkinsonism, Akathisia
	Uncommon	Dystonia (including visual disturbances and oculogyric crisis), Dyskinesia, Depressed level of consciousness
	Rare	Convulsion especially in epileptic patients
	Not known	Tardive dyskinesia which may be persistent, during or after prolonged treatment, particularly in elderly patients (see section 4.4), Neuroleptic malignant syndrome (see section 4.4), dizziness, drowsiness, tremor
<b>Psychiatric disorders</b>		
	Common	Depression
	Uncommon	Hallucination
	Rare	Confusional state, restlessness, agitation.
<b>Vascular disorder</b>		
	Common:	Hypotension, particularly with intravenous formulation
	Not known	Shock, syncope after injectable use Acute hypertension in patients with phaeochromocytoma (see section 4.3), Transient increase in blood pressure

\* Endocrine disorders during prolonged treatment in relation with hyperprolactinaemia (amenorrhoea, galactorrhoea, gynaecomastia).

The following reactions, sometimes associated, occur more frequently when high doses are used:

- Extrapyramidal symptoms: acute dystonia and dyskinesia, parkinsonian syndrome, akathisia, even following administration of a single dose of the medicinal product, particularly in children and young adults (see section 4.4).
- Drowsiness, decreased level of consciousness, confusion, hallucination.

### **Reporting of suspected adverse reactions**

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via HPRA Pharmacovigilance, Earlsfort Terrace, IRL - Dublin 2; Tel: +353 1 6764971; Fax: +353 1 6762517. Website: [www.hpra.ie](http://www.hpra.ie); E-mail: [medsafety@hpra.ie](mailto:medsafety@hpra.ie).

## **4.9 Overdose**

### **Symptoms**

Extrapyramidal disorders, drowsiness, decreased level of consciousness, confusion, hallucination, and cardio-respiratory arrest may occur.

### **Management**

In case of extrapyramidal symptoms related or not to overdose, the treatment is only symptomatic (benzodiazepines in children and/or anticholinergic anti-parkinsonian medicinal products in adults).

A symptomatic treatment and a continuous monitoring of the cardiovascular and respiratory functions should be carried out according to clinical status.

## **5 PHARMACOLOGICAL PROPERTIES**

### **5.1 Pharmacodynamic properties**

Pharmacotherapeutic group: Agents stimulating gastro-intestinal motility

ATC code: A03FA01

The action of metoclopramide is closely associated with parasympathetic nervous control of the upper gastrointestinal tract, where it has the effect of encouraging normal peristaltic action. Metoclopramide is a benzamide derivative which acts peripherally to enhance cholinergic action at muscarinic synapses and in the central nervous system to antagonize dopamine. This provides for a fundamental approach to the control of those conditions where disturbed gastrointestinal motility is a common underlying factor.

### **5.2 Pharmacokinetic properties**

Absorption:

Absorption from the gastrointestinal tract is rapid.

Biotransformation:

The drug undergoes significant first pass hepatic metabolism.

Elimination:

It is excreted in the urine as unchanged drug and metabolites in both free and conjugated form. The drug is also excreted in breast milk.

### **Renal impairment**

The clearance of metoclopramide is reduced by up to 70% in patients with severe renal impairment, while the plasma elimination half-life is increased (approximately 10 hours for a creatinine clearance of 10-50 mL/minute and 15 hours for a creatinine clearance <10 mL/minute).

### **Hepatic impairment**

In patients with cirrhosis of the liver, accumulation of metoclopramide has been observed, associated with a 50% reduction in plasma clearance.

### **5.3 Preclinical safety data**

No further information other than that which is included in other sections of the Summary of Product Characteristics.

## **6 PHARMACEUTICAL PARTICULARS**

### **6.1 List of excipients**

Sodium Metabisulphite (E223)  
Sodium Chloride  
Water for Injections  
Hydrochloric Acid  
Sodium Hydroxide

### **6.2 Incompatibilities**

Metoclopramide is reported to be incompatible with sodium bicarbonate, cephalothin sodium and other cephalosporins, and chloramphenicol. Do not mix with other drugs unless compatibility is known.

### **6.3 Shelf life**

Unopened: 3 years.  
The product should be used immediately after opening.

### **6.4 Special precautions for storage**

Keep the ampoule in the original carton in order to protect from light.  
Do not store above 25°C.

### **6.5 Nature and contents of container**

Clear glass one-point-cut (OPC) ampoules, glass type I Ph. Eur.  
Pack size: 10 x 2ml ampoules.

### **6.6 Special precautions for disposal and other handling**

For single use only  
If only part used, discard the remaining solution.  
Any unused medicinal product or waste material should be disposed of in accordance with local requirements.

## **7 MARKETING AUTHORISATION HOLDER**

Mercury Pharmaceuticals (Ireland) Ltd  
4045 Kingswood Road  
Citywest Business Park  
Co Dublin  
Ireland

## **8 MARKETING AUTHORISATION NUMBER**

PA0073/084/001

## **9 DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION**

Date of first authorisation: 11 October 1984  
Date of last renewal: 11 October 2009

## **10 DATE OF REVISION OF THE TEXT**

December 2019